Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United KingdomIPO:
16 November 1999Website:
http://www.smith-nephew.comNext earnings report:
01 August 2024Last dividends:
01 April 2024Next dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTAnalysts recommendations
Institutional Ownership
SNN Latest News
Activist investor Cevian Capital on Thursday revealed it has built up a 5% stake in British medical equipment seller Smith & Nephew, causing shares in the struggling FTSE-100 company to surge.
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
Smith & Nephew plc (NYSE:SNN) will be holding a conference call on May 1, 2024 at 3:30 AM ET to discuss their Q1 2024 Sales/Trading Statement. CEO Deepak Nath and CFO John Rogers will be participating, along with analysts from various firms including RBC Capital Markets and JPMorgan. Welcome to the Smith & Nephew Q1 2024 Results Presentation.
Smith & Nephew surged to the top of the FTSE 100 after the UK MedTech company provided a positive first-quarter report, confirming expectations of strong revenue growth for the rest of the year. Revenue increased by 2.9% to US$1.39 billion, driven by strong performances in orthopaedics (4.4%) and sports medicine (5.5%), although wound management sales decreased.
The most recent collaboration enables Smith+Nephew (SNN) to enhance its current implant offerings by incorporating the advanced navigation technology of NAVBIT.
JP Morgan has spotlighted Smith & Nephew PLC (LSE:SN) for its revenue acceleration and margin expansion potential, setting a price target of 1,300p - a 21% premium to the current stock price. Despite investor scepticism, the bank has added S&N to its Analyst Focus List (AFL), highlighting its attractive risk-reward profile in the healthcare sector.
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith & Nephew PLC (LSE:SN) kept its dividend unchanged and guided to solid growth this year as it reported 2023 results in line with improved guidance from last summer. The hip and knee replacement specialist posted results showing $5.55 billion of revenue for the past calendar year, up 7.2% on an underlying basis and 6.4% reported.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 1(current)
What type of business is Smith & Nephew?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
What sector is Smith & Nephew in?
Smith & Nephew is in the Healthcare sector
What industry is Smith & Nephew in?
Smith & Nephew is in the Medical Devices industry
What country is Smith & Nephew from?
Smith & Nephew is headquartered in United Kingdom
When did Smith & Nephew go public?
Smith & Nephew initial public offering (IPO) was on 16 November 1999
What is Smith & Nephew website?
https://www.smith-nephew.com
Is Smith & Nephew in the S&P 500?
No, Smith & Nephew is not included in the S&P 500 index
Is Smith & Nephew in the NASDAQ 100?
No, Smith & Nephew is not included in the NASDAQ 100 index
Is Smith & Nephew in the Dow Jones?
No, Smith & Nephew is not included in the Dow Jones index
When does Smith & Nephew report earnings?
The next expected earnings date for Smith & Nephew is 01 August 2024